BioPorto (BIOPOR) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.575x

Based on the latest financial reports, BioPorto (BIOPOR) has a cash flow conversion efficiency ratio of -0.575x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-20.23 Million ≈ $-3.16 Million USD) by net assets (Dkr35.18 Million ≈ $5.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

BioPorto - Cash Flow Conversion Efficiency Trend (2000–2024)

This chart illustrates how BioPorto's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BioPorto debt and liabilities for a breakdown of total debt and financial obligations.

BioPorto Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioPorto ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Media Prima Bhd
KLSE:4502
0.055x
Wanbury Limited
NSE:WANBURY
-0.053x
Bridgemarq Real Estate Services Inc
TO:BRE
-0.014x
Prozone Realty Limited
NSE:PROZONER
0.044x
ALT5 Sigma Corporation
NASDAQ:ALTS
-0.006x
New Delhi Television Limited
NSE:NDTV
1.199x
Panda Financial Holding Corp Ltd
SHG:600599
0.459x
Afluente Transmissão de Energia Elétrica S.A
SA:AFLT3
0.067x

Annual Cash Flow Conversion Efficiency for BioPorto (2000–2024)

The table below shows the annual cash flow conversion efficiency of BioPorto from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of BioPorto.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Dkr67.78 Million
≈ $10.60 Million
Dkr-83.58 Million
≈ $-13.08 Million
-1.233x -33.78%
2023-12-31 Dkr60.16 Million
≈ $9.41 Million
Dkr-55.46 Million
≈ $-8.68 Million
-0.922x -23.33%
2022-12-31 Dkr70.22 Million
≈ $10.99 Million
Dkr-52.48 Million
≈ $-8.21 Million
-0.747x +46.80%
2021-12-31 Dkr45.96 Million
≈ $7.19 Million
Dkr-64.58 Million
≈ $-10.10 Million
-1.405x -298.07%
2020-12-31 Dkr100.91 Million
≈ $15.79 Million
Dkr-35.62 Million
≈ $-5.57 Million
-0.353x +85.15%
2019-12-31 Dkr25.32 Million
≈ $3.96 Million
Dkr-60.16 Million
≈ $-9.41 Million
-2.376x -251.29%
2018-12-31 Dkr56.20 Million
≈ $8.79 Million
Dkr-38.01 Million
≈ $-5.95 Million
-0.676x -28.99%
2017-12-31 Dkr56.07 Million
≈ $8.77 Million
Dkr-29.40 Million
≈ $-4.60 Million
-0.524x -18.13%
2016-12-31 Dkr44.29 Million
≈ $6.93 Million
Dkr-19.66 Million
≈ $-3.08 Million
-0.444x -19.14%
2015-12-31 Dkr44.48 Million
≈ $6.96 Million
Dkr-16.57 Million
≈ $-2.59 Million
-0.373x +33.77%
2014-12-31 Dkr28.69 Million
≈ $4.49 Million
Dkr-16.14 Million
≈ $-2.52 Million
-0.563x -44.91%
2013-12-31 Dkr42.86 Million
≈ $6.71 Million
Dkr-16.64 Million
≈ $-2.60 Million
-0.388x -102.92%
2012-12-31 Dkr-1.15 Million
≈ $-179.93K
Dkr-15.28 Million
≈ $-2.39 Million
13.287x +484.76%
2011-12-31 Dkr3.94 Million
≈ $616.44K
Dkr-13.61 Million
≈ $-2.13 Million
-3.453x +14.59%
2010-12-31 Dkr3.31 Million
≈ $517.72K
Dkr-13.38 Million
≈ $-2.09 Million
-4.043x -368.99%
2009-12-31 Dkr15.41 Million
≈ $2.41 Million
Dkr-13.29 Million
≈ $-2.08 Million
-0.862x +2.57%
2008-12-31 Dkr15.50 Million
≈ $2.43 Million
Dkr-13.72 Million
≈ $-2.15 Million
-0.885x -84.47%
2007-12-31 Dkr29.45 Million
≈ $4.61 Million
Dkr-14.13 Million
≈ $-2.21 Million
-0.480x -62897.70%
2006-12-31 Dkr-17.62 Million
≈ $-2.76 Million
Dkr-13.46K
≈ $-2.11K
0.001x -83.18%
2005-12-31 Dkr-3.06 Million
≈ $-478.13K
Dkr-13.88K
≈ $-2.17K
0.005x -99.19%
2000-12-31 Dkr894.00K
≈ $139.87K
Dkr503.00K
≈ $78.70K
0.563x --

About BioPorto

CO:BIOPOR Denmark Diagnostics & Research
Market Cap
$96.05 Million
Dkr613.92 Million DKK
Market Cap Rank
#19333 Global
#82 in Denmark
Share Price
Dkr1.24
Change (1 day)
+9.73%
52-Week Range
Dkr0.84 - Dkr1.59
All Time High
Dkr7.78
About

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neu… Read more